View in EDS HTML Full Text PDF Full Text

Targeting PRMTs Creates Vulnerability of DNA Double-Stand Break Repair Pathways, and Potentiates Chemotherapy Efficacy in TNBC.

Saved in:
Bibliographic Details
Title: Targeting PRMTs Creates Vulnerability of DNA Double-Stand Break Repair Pathways, and Potentiates Chemotherapy Efficacy in TNBC.
Authors: Thiebaut C; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France., Martinez S; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France., Pruvost L; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France., Eve L; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France., El-Botty R; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France., Sourd L; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France., Montaudon E; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France., Dahmani A; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France., Derrien H; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France., Sentis S; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France., Poulard C; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France., Marangoni E; Laboratory of Preclinical Investigation, Translational Research Department, Institut Curie, PSL University, Paris, France., Trédan O; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; Oncology Department, Centre Leon Bérard, Lyon, France., Le Romancer M; Université Claude Bernard Lyon 1, Lyon, France.; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.; CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Source: Cancer science [Cancer Sci] 2026 May; Vol. 117 (5), pp. 1273-1285. Date of Electronic Publication: 2026 Mar 09.
Publication Type: Journal Article
Journal Info: Publisher: Wiley Publishing on behalf of the Japanese Cancer Association Country of Publication: England NLM ID: 101168776 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1349-7006 (Electronic) Linking ISSN: 13479032 NLM ISO Abbreviation: Cancer Sci Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1349-7006
DOI:10.1111/cas.70338